Oral antibiotic has captured 28% of $130 mil. U.S. erythromycin market to become the market leader with approximately $36 mil. in U.S. sales, according to F. H. Faulding, the Australian firm that licenses the drug to Parke-Davis. Faulding also reports that sales of oral doxycycline Doryx have reached $5.5 mil. in the U.S. since the product was launched in February. Doryx is also licensed to Warner-Lambert.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.